Background & Aims The risk of serious clinical outcomes following cessation of nucleos (t)
ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized …

To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …

Chronic hepatitis B virus disproportionately affects migrant communities in high-income
countries, reflecting increased migration from sub-Saharan Africa. Chronic hepatitis B virus …

Nucleoside analogues are the mainstay of treatment for patients with chronic HBV infection
but have no direct effect on covalently closed circular DNA. Long-term HBV viral …

Summary Background and Aims Current guidelines recommend long‐term nucleot (s) ide
analogue (NA) therapy for patients with HBeAg‐negative chronic hepatitis B (CHB) …

Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …

Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …

Worldwide, an estimated 296 million people are living with chronic hepatitis B virus (HBV)
infection, with a significant risk of morbidity and mortality. Current therapy with pegylated …

Chronic hepatitis B (CHB) is a major cause of chronic liver diseases in Korea and remains a
threat to public health due to its high morbidity and disease-related mortality. Since the latest …

Background Chronic hepatitis B remains a global health problem with an estimated 296
million people affected worldwide. Individuals are at risk of serious complications such as …